Lemaitre Vascular (LMAT) Senior VP Trent G. Kamke Receives Award

What Happened

• Trent G. Kamke, Senior Vice President, Operations at Lemaitre Vascular (LMAT), was credited seven dividend-equivalent awards on 2026-09-03. The individual entries were for 0.956, 0.956, 1.635, 1.960, 2.193, 2.483 and 3.674 shares, totaling 13.857 shares. Each was reported as a derivative acquisition (code A) at $0.00 per share; reported value is $0 because these are dividend-equivalent rights rather than a cash purchase or open-market trade.
• These dividend-equivalent rights are the economic equivalent of common shares but vest proportionately with the underlying restricted stock units (RSUs) or performance share units (PSUs). They are compensation-related accruals, not a purchase or sale of stock.

Key Details

• Transaction date: 2026-09-03; Filing date: 2026-09-08.
• Reported price/value: $0.00 (derivative dividend-equivalent credits).
• Shares credited (by line): 0.956; 0.956; 1.635; 1.960; 2.193; 2.483; 3.674 (total 13.857).
• Footnotes: credits relate to prior awards granted on 12/12/2022 (F1, F2), 12/8/2023 (F3, F4), 12/6/2024 (F5, F6) and 12/10/2025 (F7); each footnote confirms these dividend equivalents vest proportionately with the underlying RSU/PSU awards and are the economic equivalent of one share.
• Shares owned after the transaction are not specified in the provided excerpt.
• Timeliness: Filing occurred five days after the transaction date (filed 2026-09-08 for activity on 2026-09-03), which appears later than the typical Form 4 requirement of reporting within two business days.

Context

• Dividend-equivalent credits are routine compensation adjustments tied to existing RSU/PSU awards; they do not necessarily indicate insider sentiment about the stock since they are accrued benefits that vest with the underlying awards.
• Because these are small, fractional accruals and not open-market purchases or sales, they are generally less informative about trading intent than direct buys or sells.